G) of the reference rotaviruses used in this study have been described previously. 20, 21, 24 In addition to the BRV strains described previously, 20, 21 strain 2292B was obtained from Califomia. a The 2292B strain was adapted to growth in cell culture (S. Hammami et al., unpublished data) and passaged in a conventional colostrum-deprived (CD) calf as previously described. 28 Rotavirus reassortants (SA11 x NCDV) N4 (NCDV VP4, SA11 VP7) and S4 (SA11 VP4, NCDV VP7) 19 were used in this study. b The G serotypes of the reference BRV strains were previously characterized using G6 and G10 neutralizing serotype-specific monoclonal antibodies (MAbs) or by 2-way cross-neutralization tests (L. J. Saif et al., unpublished data) . A group C BRV, Shintoku strain, previously adapted to growth in cell culture was used as a negative contro1. 39 The bovine group B rotavirus (AT1 B strain) 25 was also passaged in CD calves as previously described. 28 Rotavirus dsRNA in extracted samples was analyzed by PAGE to examine the genomic electropherotypes as previously described. 24 The discontinuous buffer system of Laemmli was utilized, and dsRNA was resolved in 10% polyacrylamide slab gels. Electrophoresis was conducted at 12 mA for 14-16 hours. The dsRNA bands were visualized by silver staining or staining with ethidium bromide c (0.5 µg/ ml).
Hyperimmune antisera were made by multiple intramuscular or subcutaneous injections of partially purified virions into guinea pigs, with Freund's complete adjuvant for the first injection. Blood samples were collected from guinea pigs after a high antibody titer against the homologous virus was confirmed by neutralization assays. 29 The serum was collected, heat inactivated for 30 min at 56 C, and stored at -20 C. MAb IC3 (specific for UK BRV VP7), d MAb E7 (specific for B223 BRV VP7) e and MAbs with specificities for rotavirus subgroup 1 (hybridoma 255/60) or subgroup 2 (hybridoma 361/9) were used. d The cell culture immunofluorescence (CCIF) test was performed as previously described. 34 Confluent monolayers of MA-104 cells in 96-well plates were inoculated with serial dilutions of fecal samples obtained from the gnotobiotic calves. After 16 hours of incubation at 37 C in a 5% CO 2 incubator, the cells were fixed in 80% acetone and stained directly with fluorescein isothiocyanate-conjugated hyperimmune gnotobiotic pig anti-bovine group A rotavirus serum. 34 The fluorescent focus neutralization test was performed as described previously. 36 Neutralizing antibody titers were expressed as the reciprocal of the highest serum dilution that produced an 80% or greater reduction in numbers of fluorescent foci. The plaque-reduction virus neutralization (PRVN) test was performed in plastic 6-well plates containing MA-104 cell monolayers to determine neutralizing antibody titers of MAbs or hyperimmune antisera as previously described. 29 The PRVN titer was expressed as the reciprocal of the highest dilution of serum or ascitic fluid that produced an 80% reduction in the number of plaques, as compared with the number in virus control wells.
For cross-protection studies, 2 newborn gnotobiotic calves were used. The calves were fed and maintained as previously described.** Blood samples were collected from calves prior to initial inoculation and prior to the challenge 3 weeks later. Sera were collected, heat inactivated at 56 C for 30 minutes, and frozen at -20 C for further testing. Calf A was orally and intranasally inoculated with a filtrate of live virulent IND BRV (previously passaged in a CD calf), and calf B was orally/ intranasally inoculated with a fecal filtrate of live virulent 2292B BRV (passaged in a CD calf). The inocula were prepared by sonicating 15 ml of feces obtained from the infected CD calves, dilution 1:5 in phosphate-buffered saline and centrifugation at 800 x g for 15 minutes. The supernatants were filtered through a 0.22-µm filter and used for inoculation and challenge. The CCIF titer of each inoculum was approximately 1.0 x 10 4 fluorescent focus units/ml. Three weeks after the inoculation, calf A was challenged with the above dose of 2292B BRV and calf B was challenged with the above dose of IND BRV. Rectal swabs were collected daily from both calves for 1 week after the inoculation and after challenge and every other day for the second week after each inoculation and after challenge. The swabs were placed in 4 ml of diluent containing minimal essential medium 6 and then discarded. The swab fluid was centrifuged at 800 x g for 30 minutes at 4 C. The supernatant was frozen at -20 C for subsequent ELISA and CCIF testing. Fecal samples were also collected daily during the 2-week sampling period after each challenge and examined by immune electron microscopy 27 to detect rotaviruses and to rule out the possibility of other adventitious viruses. These fecal samples were also examined for rotavirus RNA electropherotypes by PAGE to confirm the rotavirus strain shed by the calves. Some of these samples were also used for polymerase chain reaction (PCR) amplification of partial length VP4 and VP7 genes directly from the feces. 10 Clinical signs were recorded daily and included observations on the color and consistency of stools. The stools were rated as abnormal if they were off color (bright yellow or green) and of semiliquid to liquid consistency.
The ELISA for the detection of BRV and subgroup analysis was similar to procedures described previously. 15,17,28 Samples were considered positive if their mean absorbance values on antibody-coated wells were greater than the mean plus 3 SD of the absorbance values of the negative control samples on wells with positive and negative coatings.
Genomic dsRNA was extracted with phenol/chloroform from rotavirus-infected feces or cell culture. 24 For PCR amplification using dsRNA extracted from fecal material, the dsRNA was purified using an RNA purification kit f as per the manufacturer's instructions. The purified dsRNA was boiled in 20% dimethylsulfoxide (DMSO) for 5 minutes and cooled on ice for 5 minutes. Oligonucleotide primers used in this study have been previously described. 20 Amplification of dsRNA templates required an initial reverse transcription step. Partial length VP7 cDNA (nucleotides 51-392) and VP4 cDNA (nucleotides 211-686), encompassing areas of major sequence diversity, were prepared by PCR amplification using specific primers. 20, 21 The heat-denatured dsRNA was diluted 1:4 (5% DMSO) in a reaction mixture containing 10 mM Tris (pH 8.3), 40 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol, 200 µM each of dATP, dCTP, dTTP, and dGTP, 200 ng of primers 7C and 7D (for VP7 gene) or 4C and 4D (for VP4 gene), 10 U of AMV reverse transcriptase, 2.5 units of Taq polymerase, and 20 units of an RNAse inhibitor. g The tubes were placed in a thermocycler h and incubated at 42 C to generate cDNA copies of rotavirus dsRNA. The tubes were heated at 94 C for 5 minutes and subjected to 30 amplification cycles, each consisting of 94 C for 1 minute (denaturation), 42 C for 1.5 minutes (annealing), and 72 C for 3.5 minutes (extension). The PCR products were purified by centiflex-AG cartridges g and analyzed with a 1% agarose gel using standard procedures. 3o The purified PCR products were radiolabeled using a nick translation kit i and 32 P-deoxycytidine-5'-triphosphate j ( 32 P-dCTP) (specific activity = 650 Ci/mmol) as previously described. 24 The northern and dot-blot hybridization assays were performed using previously described procedures. 20 The hybridizations were performed for 16-24 hours at 42 C (moderate stringency) or 52 C (high stringency). The Nytran mem-brane+ were washed, rinsed, blotted, and exposed to black and white negative! film with intensifying screens at -70 C for 1-7 days.
Among group A BRV, the characteristic 4-2-3-2 pattern was observed, and both long (IND, B223, Cr, NCDV) and short (2292B, OK, ID) genome electropherotypes were observed. A characteristic migration pattern was also observed for RNA from BRV serogroups B and C (4-2-2-3 and 4-3-2-2, respectively) ( Fig. 1) . Under high-stringency conditions and using a northern blot hybridization assay, the NCDV (G6) and Cr (G10) VP7 PCR probes reacted with 3 BRV strains possessing short genome electropherotypes (2292B, ID, OK) ( Fig. 2a, lanes A, C, D) and with 2 BRV strains possessing long genome electropherotypes (Cr, NCDV) ( Fig.  2a, lanes B, E) . The NCDV probe (G6) reacted with VP7 genes from the homologous RNA sample NCDV (Fig. 2b , lane E) and from the short electropherotype strains ID (Fig.  2b, lane C) and OK (Fig. 2b, lane D) . No reaction was observed with the short electropherotype strain 2292B or the long Cr (G10) strain (Fig. 2b, lanes A and B, respectively) . The Cr probe, under the same stringency conditions, reacted with the VP7 gene from the homologous RNA sample (Fig.  2c, lane B) and with strain 2292B (Fig. 2c, lane A) . No reaction was observed with strains ID, OK, and NCDV (Fig.  2c, lanes C, D, and E, respectively) . The 2292B BRV was characterized as P11 by dot-blot hybridization assays using the Cr VP4 partial length cDNA probe (data not shown).
Strain 2292B had a subgroup 1 specificity using a MAbbased ELISA. Table 1 shows the results of reciprocal crossneutralization tests to confirm the serotypic identity of the Table 1 . Virus neutralizing antibody titers* for reference bovine rotavirus (BRV) strains and strain 2292B using hyperimmune antisera and monoclonal antibodies (MAbs) to known BRV G and P serotypes. 2292B strain. Two rotaviruses were considered antigenically distinct when a 20-fold or greater difference in PRVN titers occurred between homologous and heterologous reactions. 13 Because some results were difficult to interpret because of the dual (P and G) serotype specificity of rotaviruses, MAbs and antisera to reassortant viruses were tested to resolve such discrepancies. The 2292B strain was serologically distinct from NCDV, SA11 (based on NCDV x SA11 reassortants), and IND because it was not neutralized by antisera to IND or to the reassortants N4 (NCDV VP4, SA11 VP7) and S4 (SA11 VP4, NCDV VP7). It was antigenically related to B223 and Cr strains because antiserum to each of these strains neutralized 2292B. Guinea pig hyperimmune antiserum to strain 2292B failed to neutralize the NCDV Lincoln strain but neutralized the B223 and Cr strains. Further evidence concerning these antigenic relationships was provided by MAb neutralization titers. The MAb IC3 (G6-specific MAb, UK VP7) did not neutralize 2292B, B223, or Cr but had a high neutralizing antibody titer against NCDV Lincoln and IND strains (G6). The MAb E7 (G10-specific, B223 VP7) neutralized 2292B, B223, and Cr but failed to neutralize either IND or NCDV Lincoln strains. Together, the serologic data suggested that strain 2292B had a G10 specificity. The P specificity could not be determined from these serologic results.
The results of virus shedding and clinical signs observed after inoculation and challenge of gnotobiotic calves are presented in Table 2 . Calf A, first inoculated with the live virulent IND strain of BRV, was not protected against challenge with the 2292B strain, as evidenced by virus shedding and abnormal stools after challenge. Similarly, calf B, inoculated with live virulent 2292B strain, was not protected against a challenge with the IND strain. The virus shedding and abnormal stools lasted for a longer time when calf A was challenged than when calf B was challenged (Table 2) . In some previous studies using a similar challenge system, we observed complete protection (no viral shedding or disease) when the calves were challenged with the homologous virus strains. Therefore, the results of the present studies indicated that the 2 viral strains (2292B and IND) did not induce complete cross-protection.
Using PCR amplification, partial length G (341 bp) and P (475 bp) type-specific cDNA fragments were generated using dsRNA extracted from the feces of a 2292B-infected gnotobiotic calf (Fig. 3) . These PCR products were labeled with 32 P-dCTP and used as probes in dot-blot hybridization assays. The assay included the reference BRV strains IND, ID, OK (G6, P5), NCDV (G6, P1), Cr, and B223 (G10, P11). The partial length VP7 cDNA probe was specific for G10 BRV strains, and the partial length VP4 cDNA probe was specific for P11 BRV strains, confirming the G10, P11 specificity of the 2292B BRV.
Previous studies have demonstrated prolonged viral excretion and failure of cross-protection between distinct serotypes of BRV. 40 Studies have also demonstrated the failure of the NCDV vaccine (G6, P1) to induce protection against B223 (G10, P11) or B641 (G6, P5) strains in experimentally infected gnotobiotic calves. 40 This suggests that differences in VP4, confirmed by sequence analysis, 12 may be a cause of vaccine failure. In our studies, cross-protection experiments with BRV reference strain IND (G6, P5) and the 2292B strain were done in gnotobiotic calves. Initial exposure of the gnotobiotic calf to the IND strain failed to completely protect against challenge with the heterologous strain 2292B, and vice versa. Using a similar challenge model, we previously observed that initial exposure with a BRV strain and subsequent challenge with the same strain results in complete protection (L. J. Saif et al., unpublished results). Therefore, these data suggest that the 2292B strain is antigenically distinct from the IND strain.
Epidemiologic investigations regarding rotaviruses often include a survey of genome electropherotypes, which may provide important information about the origin of the strains that are circulating among the infected animals. 35, 38 Most BRV strains have a long genome pattern. 35 However, there have been some reports of BRV isolates with short electro- pherotypes. 1, 22, 36, 37 Comparison of 3 BRV isolates from 3 sep-been described; they have a missing gene segment 11 but an arate beef herds, each possessing a short genome electro-extra band between segments 6 and 7. 23 One such genome pherotype, suggested that these viruses were distinct isolates, rearrangement involving RNA segment 11 of a BRV strain each with a slightly different electropherotype. 36 was analyzed by sequence analysis. 31 The results indicated It is unclear why some BRV strains have a short genome that the rearranged genome segment was generated by a headpattern. BRV strains with unusual genome patterns have to-tail concatamerization of 2 full-length copies of gene seg- ment 11. The upstream copy of the gene had lost its 3' end and the downstream copy had lost its 3' end. 31 Northern blot hybridization indicated that gene 11 of the VMRI strain had been rearranged and had migrated between segments 9 and 10. 22 All 3 strains described in the present study (OK, ID, 2292B) ( Fig. 1 ) may also have a rearranged gene segment 11. Gene segment 10 of the 3 short strains (ID, OK, 2292B) comigrates with the gene segment 10 of the strains with long genome patterns (Fig. 1 ). However, some or all of these short patterns may be the result of slowly migrating gene segments 10 and 11, resulting in gene segment 11 migrating into the position of gene segment 10. These gene rearrangements need to be further characterized by hybridization analysis with rotavirus gene 10 and 11 cDNA probes.
In the present study we demonstrated the presence of a G10 BRV isolate, 2292B, with a short electropherotype. This confirms the presence of G6 as well as G10 short and long electropherotypes among BRV isolates. Furthermore, the correlation between serotypes and electropherotypes observed for human rotaviruses (short electropherotypes usually restricted to subgroup 1 G2 human rotaviruses) 14 may be lacking among BRV isolates because short genome patterns are not restricted to G6 BRV strains. The G and P types of 2 other short genome pattern BRV strains, ID and OK, have been previously characterized. 20, 21 Both strains have a G6, P5 specificity, similar to the IND BRV strain.
A survey on a limited number of field BRV strains (n = 102) indicated that G6, P5 strains were predominant, followed by G10, P11 strains. 20 The P type of the vaccine strain (P1) was the least frequent in this survey. Therefore, future vaccines may be more successful if both G6, P5 and G10, P11 strains are included. The short strains, such as ID (G6, P5) and 2292B (G10, P1l), which are not so commonly found, may serve as useful vaccine candidates because they not only represent the predominant G and P types but their short and unique electropherotypic patterns may be easily distinguishable from the more common long electropherotype strains. However, additional methods such as G and P typing are necessary to differentiate between naturally occurring short strains or in vivo reassortants from the short vaccine strains.
